000 01495 a2200385 4500
005 20250514235408.0
264 0 _c20051213
008 200512s 0 0 eng d
022 _a0885-3185
024 7 _a10.1002/mds.20545
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aLang, Anthony E
245 0 0 _aTreatment of progressive supranuclear palsy and corticobasal degeneration.
_h[electronic resource]
260 _bMovement disorders : official journal of the Movement Disorder Society
_cAug 2005
300 _aS83-91 p.
_bdigital
500 _aPublication Type: Journal Article
650 0 4 _aAmantadine
_xtherapeutic use
650 0 4 _aCerebral Cortex
_xpathology
650 0 4 _aCholinesterase Inhibitors
_xtherapeutic use
650 0 4 _aCorpus Striatum
_xpathology
650 0 4 _aDonepezil
650 0 4 _aDopamine Agents
_xtherapeutic use
650 0 4 _aDopamine Agonists
_xtherapeutic use
650 0 4 _aDystonia
_xdrug therapy
650 0 4 _aGlobus Pallidus
_xpathology
650 0 4 _aHumans
650 0 4 _aIndans
_xtherapeutic use
650 0 4 _aLevodopa
_xtherapeutic use
650 0 4 _aNerve Degeneration
_xdrug therapy
650 0 4 _aPiperidines
_xtherapeutic use
650 0 4 _aSubstantia Nigra
_xpathology
650 0 4 _aSupranuclear Palsy, Progressive
_xdrug therapy
773 0 _tMovement disorders : official journal of the Movement Disorder Society
_gvol. 20 Suppl 12
_gp. S83-91
856 4 0 _uhttps://doi.org/10.1002/mds.20545
_zAvailable from publisher's website
999 _c15730138
_d15730138